Solid Biosciences Inc. (SLDB) stock
SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.23−0.25 (-3.86%)
Close on Nov 17, 2026Market cap $668.01MP/E –Yield –
Solid Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Solid Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $167.40M, up 37.9% year over year. For fiscal 2025 it was $140.33M, up 45.5% from the year before. The highest annual figure on record is $140.33M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.33M | +45.5% |
| FY2024 | Dec 31, 2024 | $96.43M | +25.9% |
| FY2023 | Dec 31, 2023 | $76.56M | -2.4% |
| FY2022 | Dec 31, 2022 | $78.42M | +33.5% |
| FY2021 | Dec 31, 2021 | $58.74M | -9.5% |
| FY2020 | Dec 31, 2020 | $64.88M | -31.5% |
| FY2019 | Dec 31, 2019 | $94.74M | +63.4% |
| FY2018 | Dec 31, 2018 | $57.97M | +45.3% |
| FY2017 | Dec 31, 2017 | $39.91M | +98.4% |
| FY2016 | Dec 31, 2016 | $20.12M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $44.27M | +36.6% |
| Q1 FY2026 | Mar 31, 2026 | $46.14M | +49.3% |
| Q4 FY2025 | Dec 31, 2025 | $38.14M | +23.9% |
| Q3 FY2025 | Sep 30, 2025 | $38.86M | +42.2% |
| Q2 FY2025 | Jun 30, 2025 | $32.42M | +66.6% |
| Q1 FY2025 | Mar 31, 2025 | $30.91M | +63.8% |
| Q4 FY2024 | Dec 31, 2024 | $30.77M | +99.1% |
| Q3 FY2024 | Sep 30, 2024 | $27.33M | +63.6% |
| Q2 FY2024 | Jun 30, 2024 | $19.46M | -1.6% |
| Q1 FY2024 | Mar 31, 2024 | $18.87M | -23.4% |
| Q4 FY2023 | Dec 31, 2023 | $15.45M | -27.4% |
| Q3 FY2023 | Sep 30, 2023 | $16.70M | +19.3% |
| Q2 FY2023 | Jun 30, 2023 | $19.78M | -14.7% |
| Q1 FY2023 | Mar 31, 2023 | $24.63M | +23.5% |
| Q4 FY2022 | Dec 31, 2022 | $21.29M | +45.9% |
| Q3 FY2022 | Sep 30, 2022 | $14.01M | -2.9% |
| Q2 FY2022 | Jun 30, 2022 | $23.18M | +49.4% |
| Q1 FY2022 | Mar 31, 2022 | $19.95M | +40.4% |
| Q4 FY2021 | Dec 31, 2021 | $14.60M | -7.2% |
| Q3 FY2021 | Sep 30, 2021 | $14.43M | -10.1% |
| Q2 FY2021 | Jun 30, 2021 | $15.51M | +15.4% |
| Q1 FY2021 | Mar 31, 2021 | $14.21M | -27.8% |
| Q4 FY2020 | Dec 31, 2020 | $15.72M | -41.9% |
| Q3 FY2020 | Sep 30, 2020 | $16.05M | -29.6% |
| Q2 FY2020 | Jun 30, 2020 | $13.45M | -37.8% |
| Q1 FY2020 | Mar 31, 2020 | $19.67M | -15.5% |
| Q4 FY2019 | Dec 31, 2019 | $27.07M | +52.4% |
| Q3 FY2019 | Sep 30, 2019 | $22.79M | +55.3% |
| Q2 FY2019 | Jun 30, 2019 | $21.61M | +59.0% |
| Q1 FY2019 | Mar 31, 2019 | $23.27M | +95.1% |
| Q4 FY2018 | Dec 31, 2018 | $17.76M | +48.7% |
| Q3 FY2018 | Sep 30, 2018 | $14.68M | +38.2% |
| Q2 FY2018 | Jun 30, 2018 | $13.59M | +57.9% |
| Q1 FY2018 | Mar 31, 2018 | $11.93M | +36.6% |
| Q4 FY2017 | Dec 31, 2017 | $11.95M | – |
| Q3 FY2017 | Sep 30, 2017 | $10.62M | – |
| Q2 FY2017 | Jun 30, 2017 | $8.61M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.73M | – |
See a number that looks wrong?